advertisement
Abstract #12607 Published in IGR 7-3
Efficacy and safety of bimatoprost for patients with open angle glaucoma or ocular hypertension in the Asia Pacific Region
Rait JL; Low CH; Leuenberger EU; Singh P; O'Rourke MT; Romani R; Wanichwecha Rungruang BAsian Journal of Ophthalmology 2005; 7: 82-90
AIM: Bimatoprost, a new treatment for open angle glaucoma and ocular hypertension, has been studied primarily under stringent clinical trial conditions. However, regulators have stipulated that drugs should also be studied in clinical practice settings. The purpose of this study was to evaluate bimatoprost in clinical practice. PATIENTS AND METHODS: This multicentre 3-month clinical practice study used an open-label non-comparative prospective design. Ophthalmologists prescribed bimatoprost 0.03% ophthalmic solution as monotherapy, replacement therapy, or adjunctive therapy for 1954 patients with open angle glaucoma or ocular hypertension who required intraocular pressure lowering. RESULTS: Bimatoprost was associated with a significant reduction in intraocular pressure (p < 0.0001), whether prescribed as monotherapy (33.3% reduction), replacement therapy (17.7% reduction), or adjunctive therapy (20.9% reduction). Bimatoprost treatment enabled significantly more patients to achieve a low target pressure compared with pre-existing treatment (p < 0.0001). Significant reductions in intraocular pressure after bimatoprost treatment occurred regardless of baseline intraocular pressure and among patients whose intraocular pressure had been difficult to control. Bimatoprost was rated highly by patients and ophthalmologists, had a favourable safety profile, and was well tolerated. CONCLUSIONS: In a clinical practice setting with a broad range of patients, bimatoprost was well tolerated and provided substantial reductions in intraocular pressure.
Dr. J.L. Rait, Centre for Eye Research Australia, Department of Ophthalmology, Royal Victorian Eye and Ear Hospital, Locked Bag 8, East Melbourne, Vic. 3002, Australia
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
